Skandinaviska Enskilda Banken (SEB)’s Sinovac Biotech, Ltd SVA Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Sell	40,000 -40,000	-50%	–	﹤0.01%	208
2026 Q1	$0	Buy	80,000 +40,000	+100%	–	﹤0.01%	735
2025 Q4	$0	Hold	40,000	–	–	﹤0.01%	849
2025 Q3	$0	Hold	40,000	–	–	﹤0.01%	907
2025 Q2	$0	Buy	+40,000	New	–	﹤0.01%	918
2024 Q3	–	Sell	-40,000	Closed	–	–	865
2024 Q2	$0	Hold	40,000	–	–	﹤0.01%	833
2024 Q1	$0	Buy	+40,000	New	–	﹤0.01%	988
2023 Q4	–	Sell	-40,000	Closed	–	–	1001
2023 Q3	$0	Hold	40,000	–	–	﹤0.01%	1018
2023 Q2	$259K	Buy	+40,000	New	+$259K	﹤0.01%	845
2022 Q4	–	Sell	-40,000	Closed	-$259K	–	945
2022 Q3	$259K	Hold	40,000	–	–	﹤0.01%	790
2022 Q2	$259K	Buy	+40,000	New	+$259K	﹤0.01%	867
2022 Q1	–	Sell	-40,000	Closed	-$259K	–	1095
2021 Q4	$259K	Hold	40,000	–	–	﹤0.01%	888
2021 Q3	$259K	Hold	40,000	–	–	﹤0.01%	910
2021 Q2	$259K	Hold	40,000	–	–	﹤0.01%	937
2021 Q1	$259K	Hold	40,000	–	–	﹤0.01%	993
2020 Q4	$259K	Hold	40,000	–	–	﹤0.01%	983
2020 Q3	$259K	Hold	40,000	–	–	﹤0.01%	891
2020 Q2	$259K	Hold	40,000	–	–	﹤0.01%	890
2020 Q1	$259K	Hold	40,000	–	–	﹤0.01%	817
2019 Q4	$259K	Hold	40,000	–	–	﹤0.01%	850
2019 Q3	$259K	Buy	+40,000	New	+$259K	﹤0.01%	832

Other funds holding SVA

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Horizon Investments Charlotte, North Carolina $9.13B AUM 34.49% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s SVA Position: Q2 2026 in Review

Skandinaviska Enskilda Banken (SEB) reduced its Sinovac Biotech, Ltd (SVA) stake by 50% in Q2 2026, cutting 40,000 shares and leaving 40,000 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #208.

Skandinaviska Enskilda Banken (SEB) first reported a position in SVA in Q3 2019 and has held it in 21 quarters since. The position peaked at $259K in Q2 2023. 29 funds tracked by Wall St. Rank hold SVA as of Q2 2026.

Skandinaviska Enskilda Banken (SEB) held 40,000 shares of Sinovac Biotech, Ltd worth $0 as of Q2 2026.
Skandinaviska Enskilda Banken (SEB) sold 40,000 Sinovac Biotech, Ltd shares in Q2 2026.
Sinovac Biotech, Ltd made up ﹤0.01% of Skandinaviska Enskilda Banken (SEB)'s portfolio in Q2 2026, its #208 holding.
Skandinaviska Enskilda Banken (SEB) first reported a position in Sinovac Biotech, Ltd in Q3 2019 and has held it in 21 quarters since.
Skandinaviska Enskilda Banken (SEB)'s Sinovac Biotech, Ltd position peaked at $259K in Q2 2023.
29 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q2 2026, filed 10 Aug 2026.